- Home
- Publications
- Publication Search
- Publication Details
Title
Hepatitis C virus management: potential impact of nanotechnology
Authors
Keywords
Hepatitis C virus, Drug delivery system, HCV genotypes, Nanoparticles
Journal
Virology Journal
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-05-02
DOI
10.1186/s12985-017-0753-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture
- (2017) Daniel Sepúlveda-Crespo et al. Nanomedicine-Nanotechnology Biology and Medicine
- Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection
- (2016) Maria Ripoli et al. Journal of Biomedical Nanotechnology
- Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
- (2016) Stefan Zeuzem et al. JOURNAL OF HEPATOLOGY
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics
- (2015) Jinjin Zhang et al. BIOMATERIALS
- Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
- (2015) Gregory J. Dore et al. GASTROENTEROLOGY
- Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection
- (2015) C. A. M. Stedman et al. HAEMOPHILIA
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference
- (2015) Josune Torrecilla et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1
- (2015) P. Kwo et al. JOURNAL OF HEPATOLOGY
- Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro
- (2015) Xiaofeng Hang et al. JOURNAL OF VIROLOGICAL METHODS
- Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
- (2015) Christophe Hézode et al. LANCET
- Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
- (2015) Anita Kohli et al. LANCET INFECTIOUS DISEASES
- A galactose-functionalized dendritic siRNA-nanovector to potentiate hepatitis C inhibition in liver cells
- (2015) Abirami Lakshminarayanan et al. Nanoscale
- Avoiding treatment failures associated with HCV resistance
- (2015) Jean-Michel Pawlotsky Nature Reviews Gastroenterology & Hepatology
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
- (2015) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent advances and future directions in the management of hepatitis C infections
- (2015) Victoria Belousova et al. PHARMACOLOGY & THERAPEUTICS
- Modeling The Cost-Effectiveness of The All Oral, Direct-Acting Antiviral Regimen Daclatasvir Plus Sofosbuvir In Patients Co-Infected With Hepatitis C Virus (Hcv) And Hiv
- (2015) P McEwan et al. VALUE IN HEALTH
- Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection
- (2015) Marc Bourlière et al. Expert Review of Gastroenterology & Hepatology
- Development of microRNA therapeutics is coming of age
- (2014) E. van Rooij et al. EMBO Molecular Medicine
- Global distribution and prevalence of hepatitis C virus genotypes
- (2014) Jane P. Messina et al. HEPATOLOGY
- O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY
- (2014) R. Esteban et al. JOURNAL OF HEPATOLOGY
- Development of Biodegradable Nanoparticles for Liver-Specific Ribavirin Delivery
- (2014) Tsutomu Ishihara et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Phosphorylation of Hepatitis C Virus RNA Polymerases Ser29 and Ser42 by Protein Kinase C-Related Kinase 2 Regulates Viral RNA Replication
- (2014) S.-H. Han et al. JOURNAL OF VIROLOGY
- Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection
- (2013) Jinjin Zhang et al. BIOMATERIALS
- P19: Ribavirin-boronic acid loaded nanoparticles: a possible route to improve hepatitis C treatment
- (2013) Y Abo-zeid et al. JOURNAL OF VIRAL HEPATITIS
- Treatment of HCV Infection by Targeting MicroRNA
- (2013) Harry L.A. Janssen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
- (2013) Stefanie A. Mortimer et al. NUCLEIC ACIDS RESEARCH
- Anti−Hepatitis C Virus Drugs in Development
- (2012) Esperance A.K. Schaefer et al. GASTROENTEROLOGY
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
- (2012) Christoph Welsch et al. GUT
- Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex
- (2012) T. Shimakami et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Current status and future directions in the management of chronic hepatitis C
- (2012) Wosen Aman et al. Virology Journal
- Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown
- (2011) Soo-Ryoon Ryoo et al. BIOMATERIALS
- Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naive Infected Individuals
- (2011) S. Fonseca-Coronado et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
- (2011) Ann D Kwong et al. NATURE BIOTECHNOLOGY
- Multiple effects of silymarin on the hepatitis C virus lifecycle
- (2010) Jessica Wagoner et al. HEPATOLOGY
- Nanomedicine–Nanoscale Drugs and Delivery Systems
- (2010) Surya Singh JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
- Nanotechnology solutions for infectious diseases in developing nations
- (2009) Alejandro Sosnik et al. ADVANCED DRUG DELIVERY REVIEWS
- Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase
- (2009) Abdelhakim Ahmed–Belkacem et al. GASTROENTEROLOGY
- Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
- (2009) R. E. Lanford et al. SCIENCE
- Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus
- (2008) M. D. Bobardt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A virocidal amphipathic -helical peptide that inhibits hepatitis C virus infection in vitro
- (2008) G. Cheng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started